» Articles » PMID: 33801023

Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease

Overview
Journal Nutrients
Date 2021 Apr 3
PMID 33801023
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic associated fatty liver disease (MAFLD) is a new concept where the presence of both fatty liver and metabolic abnormality are necessary for diagnosis. Several studies have reported that altered gut microbiome is closely associated with metabolic diseases and non-alcoholic fatty liver disease. However, the studies on MAFLD population are scarce. This prospective study aimed to identify differences in gut microbiome between patients with MAFLD and healthy controls in Korean population. In this study, patients with MAFLD and age, sex-matched healthy controls were included, and their stool samples were collected. Taxonomic composition of gut microbiota was analyzed using 16S ribosomal ribonucleic acid pyrosequencing. Twenty-two MAFLD patients and 44 healthy controls were included. Taxonomic diversity was lower in patients with MAFLD in the aspect of alpha and beta diversity. The differences were also found at phylum, class, family, and genus levels between the two groups. Phylum , family , genus abundance was significantly increased and genus was significantly decreased in patients with MAFLD. In addition, butyrate-producing bacteria were decreased and ethanol-producing bacteria were increased in patients with MAFLD. The composition of gut microbiome was different between MAFLD and healthy controls in Korean population. This could offer potential targets for therapeutic intervention in MAFLD.

Citing Articles

The association between immunoinflammatory biomarkers NLR, PLR, LMR and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Yang Y, He X, Tan S, Qu X, Huang W, Cai J Clin Exp Med. 2025; 25(1):39.

PMID: 39812894 PMC: 11735594. DOI: 10.1007/s10238-024-01539-1.


Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Scarpellini E, Scarcella M, Tack J, Scarlata G, Zanetti M, Abenavoli L Antioxidants (Basel). 2024; 13(11).

PMID: 39594528 PMC: 11591341. DOI: 10.3390/antiox13111386.


Synergistic activity of m-induced ferroptosis via expansion of IFN-γCD8 T cell population in advanced hepatocellular carcinoma treated with sorafenib.

Yu H, Lin G, Jiang J, Yao J, Pan Z, Xie H Gut Microbes. 2024; 16(1):2410474.

PMID: 39353096 PMC: 11445893. DOI: 10.1080/19490976.2024.2410474.


Soybean oil-based HFD induces gut dysbiosis that leads to steatosis, hepatic inflammation and insulin resistance in mice.

Jacob T, Sindhu S, Hasan A, Malik M, Arefanian H, Al-Rashed F Front Microbiol. 2024; 15:1407258.

PMID: 39165573 PMC: 11334085. DOI: 10.3389/fmicb.2024.1407258.


Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease.

Zhong H, Zhuang Y, Xie X, Song J, Wang S, Wu L Gut Microbes. 2024; 16(1):2372881.

PMID: 38940400 PMC: 11216104. DOI: 10.1080/19490976.2024.2372881.


References
1.
Dao M, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger E . Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2015; 65(3):426-36. DOI: 10.1136/gutjnl-2014-308778. View

2.
Lee G, You H, Bajaj J, Joo S, Yu J, Park S . Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun. 2020; 11(1):4982. PMC: 7536225. DOI: 10.1038/s41467-020-18754-5. View

3.
Leung C, Rivera L, Furness J, Angus P . The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016; 13(7):412-25. DOI: 10.1038/nrgastro.2016.85. View

4.
Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

5.
Vrieze A, Holleman F, Zoetendal E, de Vos W, Hoekstra J, Nieuwdorp M . The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia. 2010; 53(4):606-13. PMC: 2830587. DOI: 10.1007/s00125-010-1662-7. View